Zepbound vs Ozempic Side Effects: Clinical Comparison

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Neither Zepbound nor Ozempic is inherently worse in terms of side effects; both belong to the GLP-1 receptor agonist class but target different receptors and carry distinct pharmacological profiles. Clinical data shows side effect severity depends more on individual factors—genetics, dose escalation speed, and baseline metabolic state—than on the medication itself.

For patients exploring GLP-1 peptide therapies, understanding your personal risk factors for adverse effects can inform smarter treatment decisions. PlexusDx focuses on precision wellness by identifying genetic predispositions in peptide pathways, allowing providers to tailor therapy selection and dosing to your unique biology.

Mechanism Differences and Side Effect Profiles

Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes. Zepbound (tirzepatide) is a GIP/GLP-1 receptor agonist—it activates two hormone receptors instead of one. This dual mechanism may explain differences in gastrointestinal tolerability and appetite suppression intensity reported in clinical trials.

Both medications slow gastric emptying and signal satiety, leading to nausea, vomiting, and constipation in some patients. Data from the SURMOUNT and SELECT trials suggest tirzepatide users report slightly higher rates of nausea at higher doses, though discontinuation rates due to side effects remain low across both drug classes.

Side Effect Comparison: Frequency and Severity Across Clinical Trials

Clinical trial data reveals overlapping but distinct side effect profiles. Both medications are well-tolerated overall, with most adverse events occurring during dose escalation and resolving as the body adapts. The following table summarizes key findings from major efficacy trials.

Side Effect	Ozempic (Semaglutide)	Zepbound (Tirzepatide)	Clinical Notes
Nausea	20-30% (mild-moderate)	25-40% (dose-dependent)	Higher in tirzepatide at 15mg dose; often transient
Vomiting	2-5%	4-7%	Rare at lower doses; improves with slower titration
Constipation	19-27%	22-28%	Most common GI side effect; responds to hydration and fiber
Diarrhea	22-27%	15-22%	More frequent with semaglutide; GIP agonism may mitigate in tirzepatide

Genetic and Metabolic Factors That Influence Tolerability

Individual side effect severity is not random; genetic variants in GIPR, and FTO pathways may predispose some patients to more pronounced gastrointestinal responses or metabolic shifts. A patient with specific GLP1R gene variants may experience heightened satiety signaling, while GIPR variants can influence glucose regulation and appetite control timing.

Baseline metabolic state—insulin resistance, liver function, and kidney clearance—also modulate drug tolerability. Patients with rapid gastric emptying baseline, or those prone to dehydration, may report more severe nausea during initiation. Conversely, slower titration schedules and adequate hydration can substantially reduce early adverse events in susceptible individuals.

Safety Considerations and Who Should Discuss These Options with a Provider

Both Zepbound and Ozempic are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pancreatitis risk, though rare, requires monitoring. Pregnant or breastfeeding patients should not use either medication. Patients with diabetic retinopathy or severe kidney disease warrant careful provider assessment.

If you experience persistent vomiting, dehydration, severe abdominal pain, or signs of pancreatitis during therapy, contact your healthcare provider immediately. A qualified provider should assess your individual risk factors, baseline health status, and medication history before recommending either drug. Dose adjustment or switching between peptide classes may be appropriate if side effects become intolerable.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test can help provide context for why you may experience side effects differently than others. The test analyzes key variants in GIPR and FTO, and MC4R pathways—genetic markers that influence peptide sensitivity, appetite regulation, and metabolic response. These insights should be interpreted with your qualified healthcare provider to support a more informed treatment conversation.

The genetic test does not predict your exact response to Zepbound, Ozempic, or compounded peptide options; it reveals predispositions in the biological pathways these medications activate. For example, if you carry specific GLP1R variants associated with heightened receptor sensitivity, your provider may recommend slower titration or a lower starting dose to minimize nausea.

By combining genetic insights with clinical evidence, you and your provider can make a more personalized decision about which peptide option—whether branded or compounded—aligns with your biology and tolerability profile. This precision approach may reduce trial-and-error adjustments and improve long-term adherence to treatment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Do these two medications act on the same receptors?

No. The article says Ozempic, which is semaglutide, is a GLP-1 receptor agonist approved for type 2 diabetes, while Zepbound, which is tirzepatide, activates both the GIP and GLP-1 receptors. It suggests that dual mechanism explains the reported differences in gastrointestinal tolerability and appetite suppression intensity between the two products.

Which side effect does the comparison table say is more common with semaglutide than tirzepatide?

Diarrhea. The article's table lists it as more frequent with semaglutide and speculates that GIP agonism may moderate it in tirzepatide. The same table places nausea and vomiting somewhat higher for tirzepatide and puts constipation close between the two, calling constipation the most common gastrointestinal complaint overall and noting it responds to hydration and fiber.

Does the article say most people abandon treatment because of side effects?

No. The article says both medications are generally well tolerated, that most adverse events occur while a strength is being raised and settle as the body adapts, and that discontinuation rates due to side effects remain low for both. It frames severity as depending more on individual factors and the pace of escalation than on which product someone takes.

Which symptoms does the post say require an immediate call during therapy?

The post says to contact your healthcare provider immediately for persistent vomiting, dehydration, severe abdominal pain, or signs of pancreatitis. It adds that pregnant or breastfeeding patients should not use either medication, and that patients with diabetic retinopathy or severe kidney disease need careful provider assessment before either product is considered.

What baseline factors does the article say make early nausea worse?

The article points to baseline metabolic state, including insulin resistance, liver function, and kidney clearance, and says patients with faster baseline gastric emptying or a tendency toward dehydration may report more severe nausea at the start. It says a slower pace of escalation and adequate hydration can substantially reduce early adverse events in susceptible individuals.

Related Reading

• Zepbound Side Effects
• Ozempic Side Effects
• Zepbound Vs Ozempic 2
• Ozempic Vs Zepbound 2

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.